FDA Sets June 10 Advisory Panel Meeting on Eli Lilly Alzheimer's Drug
By Colin Kellaher
Eli Lilly on Tuesday said the U.S. Food and Drug Administration has set June 10 as the date for its advisory committee meeting on the drugmaker's proposed Alzheimer's disease drug donanemab.
An FDA decision on whether to approve donanemab for the memory-robbing brain disorder had been expected in the first quarter, but Eli Lilly in early March said the agency would convene an advisory panel to further understand topics related to evaluating the safety and efficacy of the drug in a pivotal Phase 3 study.
Eli Lilly's chief scientific officer, Daniel Skovronsky, said during the company's earnings conference call last week that the Indianapolis company remains confident in donanemab's potential "to offer very meaningful benefits to patients."
The FDA often turns to advisory committees to obtain advice from experts who work outside of the government when a scientific, technical or policy question arises, such as whether an unapproved product is safe and effective.
The agency was expected to approve donanemab early this year as a competitor to Leqembi from Eisai and Biogen after pushing the decision out from late last year.
After Eli Lilly announced the FDA's plans for the advisory committee meeting, analysts said they still expect the agency to approve the drug.
The FDA usually follows the advice of its advisory committees, but it isn't bound by the recommendations. The FDA went against a negative vote when it approved Aduhelm, the ill-fated earlier Alzheimer's drug from Eisai and Biogen, in 2021.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 07, 2024 10:55 ET (14:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now